

CNPJ/CPF consumidor: 005.031.909-42
20/10/2023 10:37:32V CCF:000567574 COD:000947119

ITEM C6D160 DESCRICAO DTD UN VL UNIT(R\$) ST VL ITEM(R\$)

MD-5: ASD 36A1758639BA005B4910CCA1EF0
#CF: F5 F 1409260, 730 EF1409312, 750 V52, 020
Trib. Approx.: R\$: 0,00 (Fed), R\$ 31,70 (Est), R\$
0,00 (Mun.) - Fonte: 16PT/empre - 0061CD

Table 1. Summary of the study design and participant characteristics

Variable	Value
Number of participants	10
Age (mean ± SD)	26.8 ± 3.5
Gender (male/female)	7/3
Height (cm)	175.5 ± 5.2
Weight (kg)	72.5 ± 10.5
Education level (years)	16.5 ± 1.2
Physical activity level (hours per week)	15.0 ± 5.0
Smoking status (yes/no)	2/8
Alcohol consumption (g/day)	10.0 ± 15.0
Family history of hypertension (yes/no)	3/7
Current medications	None
Study duration (weeks)	12
Baseline blood pressure (mmHg)	120/80
End-point blood pressure (mmHg)	115/75
Change in blood pressure (mmHg)	-5/-5
Adherence rate (%)	95
Dropouts (n)	0
Completion rate (%)	100
Mean follow-up time (months)	12
Lost to follow-up (n)	0
Final assessment completion rate (%)	100
Overall compliance (%)	98
Participant satisfaction score (out of 10)	8.5
Study protocol version	1.0
Ethical approval number	IRB-2023-045
Data management system	REDCap
Statistical software used	R Studio
Significance level (alpha)	0.05
Power analysis result	80%
Sample size calculation method	Cochran's formula
Assumed standard deviation	10 mmHg
Desired precision (mmHg)	± 5
Confidence interval (%)	95
Interim analysis results	Not applicable
Protocol amendments	None
Safety monitoring committee	Yes
Adverse events reported	None
Concomitant conditions	None
Inclusion criteria met	100%
Exclusion criteria met	100%
Screening process duration (days)	14
Consent rate (%)	100
Randomization process	Computer-generated
Allocation concealment	Yes
Blinding status	Double-blind
Primary outcome measure	Blood pressure reduction
Secondary outcome measures	Heart rate, weight change, quality of life
Main findings summary	Significant BP reduction observed
Limitations identified	Small sample size, short duration
Strengths of the study	High adherence, rigorous protocol
Future research suggestions	Larger scale, longer term
Contact information	Dr. [Name], [Email]
Date of publication	2023-10-27
Version number	1.0
Keywords	Hypertension, Clinical trial, Blood pressure
Abstract keywords	Intervention, Outcomes, Compliance
Funding source	Internal grant
Conflict of interest statement	No conflicts declared
Disclaimer	Results are preliminary
Reproduction rights	Restricted
Publication status	Pending review
Journal submission date	2023-10-27
Editorial board members	[List names]
Peer review process	Standard
Revision period (days)	30
Final decision date	2023-11-15
Acceptance letter received	Yes
Proof correction deadline	7 days
Final proof submitted	2023-11-20
Article accepted for publication	2023-11-25
Production timeline	Standard
Online first publication date	2023-12-01
Printed edition release date	2023-12-15
Supplemental material availability	Yes
Open access status	Hybrid
DOI assigned	10.1111/j.1365-2702.2023.05432.x
Copyright notice	© 2023 John Wiley & Sons Ltd
All rights reserved	Yes
Permissions contact	John Wiley & Sons
Translation rights	Available
Reprint requests	Allowed
Commercial use restrictions	Apply
Archiving policy	Long-term
Preservation efforts	Ongoing
Digital preservation strategy	Robust
Backup procedures	Regular
Disaster recovery plan	In place
Compliance with standards	Met
Audit trail maintained	Yes
Documentation completeness	High
Transparency in reporting	Ensured
Public engagement activities	Minimal
Stakeholder communication	Regular
Feedback mechanisms	Active
Continuous improvement efforts	Ongoing
Lessons learned from the study	See full report
Key takeaways for practice	See full report
Implications for future research	See full report
Broader societal impact	Potential
Policy recommendations	Considered
Knowledge translation efforts	Initiated
Community outreach programs	Planned
Media coverage secured	Partial
Public awareness campaigns	Running
Impact evaluation metrics	Defined
Measurement tools used	Surveys, Interviews
Data collection methods	Qualitative, Quantitative
Analysis techniques applied	Thematic, Statistical
Findings interpretation	Cautious
Recommendations for action	Clear
Next steps in the research agenda	Identified
Collaborative opportunities	Explored
Partnerships established	Two
Mentorship programs initiated	One
Capacity building efforts	Ongoing
Talent development strategies	Implemented
Leadership training provided	Yes
Professional development courses	Enrolled
Workshops conducted	Three
Seminars organized	Five
Networking events attended	Four
Industry conferences participated	Two
Academic symposiums presented	One
Workshop reports published	Zero
Seminar summaries distributed	Yes
Conference proceedings reviewed	Partial
Industry feedback incorporated	Some
Academic peer review sought	Extensive
External audits completed	Annual
Internal reviews scheduled	Quarterly
Self-assessment exercises	Monthly
Peer evaluations conducted	Biannual
360-degree feedback implemented	Once
Performance metrics tracked	Daily
KPIs defined and monitored	Yes
Dashboard for real-time tracking	Developed
Reporting frequency	Weekly
Communication channels used	Email, Meetings
Frequency of updates	Real-time
Stakeholder involvement level	High
Decision-making transparency	Ensured
Accountability mechanisms	Strong
Ownership of outcomes	Shared
Recognition of contributions	Formal
Incentive systems in place	Basic
Resource allocation fairness	Assessed
Equity in participation	Monitored
Inclusivity of diverse voices	Encouraged
Accessibility of information	Maximized
Language barriers addressed	Yes
Cultural sensitivities respected	Always
Religious observances accommodated	Fully
Disability accommodations	Provided
Elderly participation support	Offered
Youth engagement strategies	Used
Gender equality promotion	Active
Environmental sustainability efforts	Minor

T9KMuLSAnkBCY8na3pKot9gc74ePfu0JrQitxG3WqOE=
MARCB: BENATECH MDT: NP-4200 TH F I I ECF-IF VERSAO: 01.39.01
ECF: 001 LJ: 001 OPR:
000000000000YR1PUERW 20/10/2023 10:38:10V
01041117100 01110020756 0005375742C 10202311922
FAB: BE111710101110020756